See more : York Harbour Metals Inc. (YORKF) Income Statement Analysis – Financial Results
Complete financial analysis of Connect Biopharma Holdings Limited (CNTB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Connect Biopharma Holdings Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Bubs Australia Limited (BUBSF) Income Statement Analysis – Financial Results
- Property Solutions Acquisition Corp. II (PSAG) Income Statement Analysis – Financial Results
- Mediobanca Banca di Credito Finanziario S.p.A. (MB.MI) Income Statement Analysis – Financial Results
- Paz Oil Company Ltd. (PZOL.TA) Income Statement Analysis – Financial Results
- Citrix Systems, Inc. (0HYR.L) Income Statement Analysis – Financial Results
Connect Biopharma Holdings Limited (CNTB)
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 988.00K | 1.03M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -988.00K | -1.03M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 51.91M | 95.26M | 81.34M | 23.12M | 15.44M |
| General & Administrative | 14.52K | 20.37M | 19.23M | 7.31M | 1.41M |
| Selling & Marketing | 13.51M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.53M | 20.37M | 19.23M | 7.31M | 1.41M |
| Other Expenses | -4.35M | -940.31K | -2.98M | -1.07M | -411.44K |
| Operating Expenses | 62.07M | 114.69M | 97.59M | 29.36M | 16.44M |
| Cost & Expenses | 62.07M | 114.69M | 97.59M | 29.36M | 16.44M |
| Interest Income | 5.20K | 1.56M | 97.67K | 109.84K | 154.65K |
| Interest Expense | 0.00 | 21.03K | 6.91K | 6.43K | 7.69K |
| Depreciation & Amortization | 988.00K | 1.01M | 640.98K | 221.05K | 114.61K |
| EBITDA | -58.37M | -111.31M | -204.93M | -118.21M | -24.78M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -62.07M | -117.66M | -99.15M | -30.30M | -15.99M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.69M | -403.66K | -103.21M | -89.07M | -8.41M |
| Income Before Tax | -59.38M | -116.12M | -204.94M | -119.37M | -24.46M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 120.00K | 297.52K | 266.47K | 934.46K | -442.49K |
| Net Income | -59.50M | -116.42M | -205.21M | -120.30M | -24.02M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.08 | -14.50 | -25.00 | -14.45 | -3.02 |
| EPS Diluted | -1.08 | -14.50 | -25.00 | -14.45 | -3.02 |
| Weighted Avg Shares Out | 55.07M | 55.04M | 52.27M | 53.94M | 55.82M |
| Weighted Avg Shares Out (Dil) | 55.07M | 55.04M | 52.27M | 53.94M | 55.82M |
Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse
Connect Biopharma Completes Enrollment of CBP-201 Global Phase 2 Clinical Trial in Moderate-to-Severe Atopic Dermatitis
Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of Connect Biopharma Holdings Limited
US IPO Weekly Recap: The IPO Market Heats Up In An 11 IPO Week
Qiming's Portfolio Company Connect Biopharma Lists on Nasdaq
Source: https://incomestatements.info
Category: Stock Reports